A patient with subcutaneous-insulin resistance treated by insulin lispro plus heparin.
Severe resistance to subcutaneous insulin but sensitivity to intravenous insulin persisted for 11 years in a 23-year-old diabetic woman. Several therapeutic trials revealed that (1) intravenous regular insulin improved her metabolic control; (2) continuous subcutaneous infusion (CSII) treatment with regular insulin or insulin lispro caused hyperglycemic period with hypoinsulinemia and hypoglycemic period with hyperinsulinemia alternately; (3) adding heparin to insulin lispro in CSII resulted in dramatic increase of serum insulin level and improvement of glycemic control; and (4) regular insulin plus heparin in CSII could not increase serum insulin level and thus the glycemic values was not improved. From these results, the patient followed the insulin lispro plus heparin protocol and obtained a better glycemic control without any adverse events. Effectiveness of this therapy may lead us to further understanding of pathophysiology of this syndrome.
Tokuyama
Y
Y
Diabetes Center, Kasori Hospital, 1835-1, Kasori, Wakaba-ku, Chiba 264-9100, Japan. yt4486yt@yahoo.co.jp
Nozaki
O
O
Kanatsuka
A
A
D000279:Administration, Cutaneous; D000328:Adult; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D061268:Insulin Lispro; D007333:Insulin Resistance / Q000502:physiology*
D007004:Hypoglycemic Agents; D007328:Insulin; D061268:Insulin Lispro; D006493:Heparin